FIG. 3.
Pathology of DOX-treated adult DTg mice. (A) Cumulative incidence of mortality in DOX-treated DTg mice from different transactivator founder lines. Mice (n = 8 to 10) were treated with DOX (2 mg/ml) for up to 6 months, and the cumulative incidence of mortality was plotted as the percentage of surviving mice. (B) Commassie blue-stained sodium dodecyl sulfate-polyacrylamide gel showing proteinuria, apparent as 66-kDA serum albumin in urine from DOX-treated mice. F, female; M, male; WT, wild-type; C, control CD4C/HIVNef. (C) Histological sections of lungs and kidneys of DOX-treated and untreated DTg mice from the F176042 and F176043 transactivator founder lines, shown at low magnification. Note the glomerulosclerosis and tubular atrophy and dilation in kidneys as well as the lymphocytic interstitial infiltration in lungs of DOX-treated DTg mice.